NASDAQ:AVDL Avadel Pharmaceuticals - AVDL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Avadel Pharmaceuticals plc Please log in to your account or sign up in order to add this asset to your watchlist. $7.66 +0.31 (+4.22%) (As of 02/2/2023 12:00 AM ET) Add Compare Share Share Today's Range$7.39▼$7.8150-Day Range$6.41▼$10.0052-Week Range$1.05▼$10.02Volume265,006 shsAverage Volume389,692 shsMarket Capitalization$473.23 millionP/E RatioN/ADividend YieldN/APrice Target$10.71 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Avadel Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside39.9% Upside$10.71 Price TargetShort InterestHealthy5.88% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.85Based on 4 Articles This WeekInsider TradingAcquiring Shares$53,400 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.01) to ($0.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector258th out of 1,030 stocksPharmaceutical Preparations Industry117th out of 502 stocks 3.4 Analyst's Opinion Consensus RatingAvadel Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.71, Avadel Pharmaceuticals has a forecasted upside of 39.9% from its current price of $7.66.Amount of Analyst CoverageAvadel Pharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.88% of the float of Avadel Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAvadel Pharmaceuticals has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Avadel Pharmaceuticals has recently decreased by 17.53%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAvadel Pharmaceuticals does not currently pay a dividend.Dividend GrowthAvadel Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVDL. Previous Next 3.8 News and Social Media Coverage News SentimentAvadel Pharmaceuticals has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Avadel Pharmaceuticals this week, compared to 1 article on an average week.Search Interest6 people have searched for AVDL on MarketBeat in the last 30 days. This is an increase of 20% compared to the previous 30 days.MarketBeat Follows5 people have added Avadel Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Avadel Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $53,400.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 3.20% of the stock of Avadel Pharmaceuticals is held by insiders.Percentage Held by Institutions50.81% of the stock of Avadel Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Avadel Pharmaceuticals are expected to grow in the coming year, from ($2.01) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Avadel Pharmaceuticals is -3.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Avadel Pharmaceuticals is -3.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAvadel Pharmaceuticals has a P/B Ratio of 5.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Avadel Pharmaceuticals (NASDAQ:AVDL) StockAvadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its products include Bloxiverz, Vazculep, Nouress, and Akovaz. It focuses on the approval of FT218, a formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was founded in 1990 and is headquartered in Dublin, Ireland.Read More Receive AVDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AVDL Stock News HeadlinesJanuary 30, 2023 | americanbankingnews.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) Short Interest UpdateJanuary 27, 2023 | americanbankingnews.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) to Post FY2025 Earnings of $1.70 Per Share, SVB Leerink ForecastsFebruary 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 26, 2023 | americanbankingnews.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) Forecasted to Earn FY2024 Earnings of $0.15 Per ShareJanuary 24, 2023 | finance.yahoo.comAvadel Pharmaceuticals Announces Publication of Real-World Data Highlighting the Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly OxybatesJanuary 5, 2023 | seekingalpha.comAVDL Avadel Pharmaceuticals plcDecember 7, 2022 | seekingalpha.comAvadel: Lumryz Overhang Now Removed, Rate BuyNovember 26, 2022 | finance.yahoo.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) insiders placed bullish bets worth US$677k in the last 12 monthsFebruary 2, 2023 | PressReach (Ad)Stocks Positioned For The YearThis breakthrough stock has bright future this decade.November 24, 2022 | benzinga.com156K Reasons To Be Bullish On Avadel Pharmaceuticals StockNovember 18, 2022 | benzinga.comAvadel Pharmaceuticals Announces Favorable Ruling on Motion to Delist REMS Patent from FDA's Orange BookNovember 18, 2022 | seekingalpha.comAvadel Pharmaceuticals jumps on patent win in dispute with Jazz Pharma (update)November 18, 2022 | finance.yahoo.comAvadel Pharmaceuticals Announces Favorable Ruling on Motion to Delist REMS Patent from FDA’s Orange BookNovember 15, 2022 | seekingalpha.comJazz Pharmaceuticals: Q3 Results, Pipeline Cleanup, And An Unhappy FTCNovember 14, 2022 | msn.comEuropean ADRs Continue to Trend Higher in Monday TradingNovember 12, 2022 | seekingalpha.comAvadel at eight-month high as FTC comments raise prospects for lead drugNovember 10, 2022 | markets.businessinsider.comNeedham Reaffirms Their Buy Rating on Avadel Pharmaceuticals (AVDL)November 10, 2022 | finance.yahoo.comAvadel Pharmaceuticals to Present at the Jefferies London Healthcare ConferenceNovember 9, 2022 | finanznachrichten.deAvadel Pharmaceuticals plc: Avadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsNovember 9, 2022 | finance.yahoo.comAvadel Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsNovember 8, 2022 | finance.yahoo.comAvadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)November 2, 2022 | finance.yahoo.comAvadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9October 24, 2022 | finance.yahoo.comAvadel Presents New Real-World Data Describing Demographic Characteristics and Comorbidities of Patients with Narcolepsy at ANA 2022October 16, 2022 | finance.yahoo.comAvadel Pharmaceuticals plc (NASDAQ:AVDL) is definitely on the radar of institutional investors who own 39% of the companySeptember 22, 2022 | finance.yahoo.comAvadel Pharmaceuticals to Present at the Ladenburg Thalmann Healthcare ConferenceAugust 25, 2022 | seekingalpha.comAvadel gains as judge delays hearing on patent dispute with Jazz PharmaAugust 10, 2022 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About Avadel PharmaceuticalsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AVDL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Avadel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AVDL Company Calendar Last Earnings11/09/2022Today2/02/2023Next Earnings (Estimated)3/16/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVDL CUSIPN/A CIK1012477 Webwww.avadel.com Phone(531) 901-5201Fax353-1526-1077Employees66Year Founded2015Price Target and Rating Average Stock Price Forecast$10.71 High Stock Price Forecast$13.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+39.9%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($2.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-77,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-334.88% Return on Assets-51.04% Debt Debt-to-Equity RatioN/A Current Ratio2.73 Quick Ratio2.73 Sales & Book Value Annual Sales$22.33 million Price / Sales21.19 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book5.76Miscellaneous Outstanding Shares61,780,000Free Float59,802,000Market Cap$473.23 million OptionableOptionable Beta1.60 Social Links Key ExecutivesGregory J. DivisChief Executive Officer & DirectorScott MackeVice President-Supply Chain & OperationsThomas S. McHughChief Financial Officer & Senior Vice PresidentJason VaughnSenior Vice President-Technical OperationsJennifer GudemanVice President-Medical & Clinical AffairsKey CompetitorsCOMPASS PathwaysNASDAQ:CMPSGH ResearchNASDAQ:GHRSDesign TherapeuticsNASDAQ:DSGNWave Life SciencesNASDAQ:WVEEagle PharmaceuticalsNASDAQ:EGRXView All CompetitorsInsiders & InstitutionsKestra Advisory Services LLCSold 31,250 shares on 1/31/2023Ownership: 0.025%Edge Wealth Management LLCBought 14,000 shares on 1/25/2023Ownership: 0.275%Aaron Wealth Advisors LLCBought 12,642 shares on 1/24/2023Ownership: 0.020%Linda PalczukBought 2,000 shares on 12/23/2022Total: $14,400.00 ($7.20/share)Thomas S MchughBought 5,000 shares on 11/29/2022Total: $39,000.00 ($7.80/share)View All Insider TransactionsView All Institutional Transactions AVDL Stock - Frequently Asked Questions Should I buy or sell Avadel Pharmaceuticals stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avadel Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AVDL shares. View AVDL analyst ratings or view top-rated stocks. What is Avadel Pharmaceuticals' stock price forecast for 2023? 6 Wall Street analysts have issued twelve-month price objectives for Avadel Pharmaceuticals' shares. Their AVDL share price forecasts range from $5.00 to $13.00. On average, they expect the company's stock price to reach $10.71 in the next year. This suggests a possible upside of 39.3% from the stock's current price. View analysts price targets for AVDL or view top-rated stocks among Wall Street analysts. How have AVDL shares performed in 2023? Avadel Pharmaceuticals' stock was trading at $7.16 at the beginning of 2023. Since then, AVDL stock has increased by 7.4% and is now trading at $7.69. View the best growth stocks for 2023 here. Are investors shorting Avadel Pharmaceuticals? Avadel Pharmaceuticals saw a decrease in short interest during the month of January. As of January 15th, there was short interest totaling 3,340,000 shares, a decrease of 17.5% from the December 31st total of 4,050,000 shares. Based on an average trading volume of 614,300 shares, the days-to-cover ratio is presently 5.4 days. Approximately 5.9% of the company's stock are sold short. View Avadel Pharmaceuticals' Short Interest. When is Avadel Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 16th 2023. View our AVDL earnings forecast. How were Avadel Pharmaceuticals' earnings last quarter? Avadel Pharmaceuticals plc (NASDAQ:AVDL) released its earnings results on Wednesday, November, 9th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.11. What other stocks do shareholders of Avadel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avadel Pharmaceuticals investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Ciena (CIEN), AMC Entertainment (AMC), Chaarat Gold (CGH), Associated British Foods (ABF), Apollo Global Management (APO), Amarin (AMRN) and Cypress Semiconductor (CY). What is Avadel Pharmaceuticals' stock symbol? Avadel Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVDL." Who are Avadel Pharmaceuticals' major shareholders? Avadel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Edge Wealth Management LLC (0.28%), Kestra Advisory Services LLC (0.03%), Aaron Wealth Advisors LLC (0.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Eric J Ende, Gregory J Divis, Linda Palczuk, Mark Anthony Mccamish and Thomas S Mchugh. View institutional ownership trends. How do I buy shares of Avadel Pharmaceuticals? Shares of AVDL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Avadel Pharmaceuticals' stock price today? One share of AVDL stock can currently be purchased for approximately $7.69. How much money does Avadel Pharmaceuticals make? Avadel Pharmaceuticals (NASDAQ:AVDL) has a market capitalization of $475.09 million and generates $22.33 million in revenue each year. The company earns $-77,330,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. How can I contact Avadel Pharmaceuticals? Avadel Pharmaceuticals' mailing address is 10 EARLSFORT TERRACE, DUBLIN L2, D02. The official website for the company is www.avadel.com. The company can be reached via phone at (531) 901-5201, via email at investors@avadel.com, or via fax at 353-1526-1077. This page (NASDAQ:AVDL) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.